Gene,Category,IDH,Evidence_Score,Druggability,BBB_Penetration,CNS_Expression,Safety_Concern,Prior_Failure,Glioma_Trial,Viability_Score
APP,Ligand,IDHmut,2.5,2.5,3,4,1,,None,2.95
TGFBR1,Receptor,IDHwt,2.5,3.5,3,3,2,,"Galunisertib in GBM (NCT01220271, NCT01582269) - modest efficacy",2.75
ABL2,Kinase,Both,1.5,3.0,3,3,1,,None,2.62
MIF,Ligand,Both,2.5,2.5,3,3,2,,ISO-1 not tested in glioma (preclinical only),2.6
CXCR4,Receptor,Both,2.0,3.0,3,3,2,,Plerixafor + RT in GBM (NCT01977677) - phase I complete,2.55
GPR84,GPCR,Both,1.5,3.5,3,2,1,,GLPG1205 not tested in glioma (IBD/IPF only),2.55
IL1B,Ligand,Both,3.0,3.0,2,1,1,,None,2.45
IL1B,Cytokine,Both,3.0,3.0,2,1,1,,None,2.45
HMOX1,Enzyme,IDHmut,1.0,2.5,3,3,1,,None,2.42
CD74,Receptor,Both,2.5,4.0,2,3,3,,Milatuzumab not tested in glioma,2.38
CXCL8,Ligand,IDHwt,3.0,2.5,2,1,1,,None,2.38
CCR5,Receptor,IDHwt,0.5,3.0,3,2,1,,None,2.23
CD99,Receptor,IDHmut,3.0,2.5,1,3,2,,None,2.23
CCL4,Ligand,Both,3.0,1.5,2,1,1,,None,2.23
TGFB1,Ligand,IDHwt,2.5,3.5,2,2,3,,None,2.15
CEBPB,TF,IDHmut,1.0,1.5,3,3,2,,None,2.08
SPP1,Ligand,IDHwt,2.5,2.5,2,1,2,,None,2.05
IRAK2,Kinase,Both,1.5,1.0,2,2,1,,None,1.93
FN1,Ligand,IDHwt,2.5,1.5,1,1,1,,None,1.85
CD44,Receptor,Both,2.5,4.0,1,2,4,Bivatuzumab terminated (skin toxicity),None,1.78
FPR1,Receptor,Both,0.5,2.5,2,1,1,,None,1.75
TNF,Cytokine,Both,2.0,3.0,1,2,3,Infliximab not tested in glioma (infection risk),None,1.7
TNF,Ligand,Both,2.0,3.0,1,2,3,Infliximab not tested in glioma (infection risk),None,1.7
COL1A1,Ligand,IDHwt,1.5,1.5,1,1,1,,None,1.6
NCL,Receptor,Both,0.5,2.5,1,3,2,,None,1.6
ITGA5,Receptor,IDHwt,1.5,2.5,1,1,2,Volociximab terminated (no efficacy in solid tumors),None,1.55
PLAUR,Receptor,Both,0.5,2.5,1,1,2,,None,1.3
PTPRC,Receptor,Both,0.5,4.0,1,2,4,Anti-CD45 RIT not translated to solid tumors,None,1.27
